DEIR AL-BALAH, Gaza Strip (AP) — Israeli troops stormed one of the last hospitals operating in northern Gaza on Friday, forcing many staff and patients outside to strip in winter weather , the territory’s health ministry said. The army denied claims it had entered or set fire to the complex and accused Hamas of using the facility for cover. Kamal Adwan Hospital has been hit multiple times over the past three months by Israeli troops waging an offensive against Hamas fighters in surrounding neighborhoods, according to staff. The ministry said a strike on the hospital a day earlier killed five medical staff. Israel's military said it was conducting operations against Hamas infrastructure and militants in the area and had ordered people out of the hospital, but said it had not entered the complex as of Friday night. It repeated claims that Hamas militants operate inside Kamal Adwan but provided no evidence. Hospital officials have denied that. The Health Ministry said troops forced medical personnel and patients to assemble in the yard and remove their clothes. Some were led to an unknown location, while some patients were sent to the nearby Indonesian Hospital, which was knocked out of operation after an Israel raid this week. Israeli troops during raids frequently carry out mass detentions, stripping men to their underwear for questioning in what the military says is a security measure as they search for Hamas fighters. The Associated Press doesn’t have access to Kamal Adwan, but armed plainclothes members of the Hamas-led police forces have been seen in other hospitals, maintaining security but also controlling access to parts of the facilities. The Health Ministry said Israeli troops also set fires in several parts of Kamal Adwan, including the lab and surgery department. It said 25 patients and 60 health workers remained in the hospital. The account could not be independently confirmed, and attempts to reach hospital staff were unsuccessful. “Fire is ablaze everywhere in the hospital,” an unidentified staff member said in an audio message posted on social media accounts of hospital director Hossam Abu Safiya. The staffer said some evacuated patients had been unhooked from oxygen. “There are currently patients who could die at any moment,” she said. Lt. Col. Nadav Shoshani, an Israeli military spokesman, denied the accusations. “While IDF troops were not in the hospital, a small fire broke out in an empty building inside the hospital that is under control,” he said Friday night. He said a preliminary investigation found “no connection” between military activity and the fire. The Israeli military heavily restricts the movements of Palestinians in Gaza and has barred foreign journalists from entering the territory throughout the war, making it difficult to verify information. “These actions put the lives of all of these people in even more danger than what they faced before,” U.N. spokesperson Stephanie Tremblay told journalists, and noted colleagues' reports of “significant damage” to the hospital. It should be protected as international law requires, she added. Since October, Israel’s offensive has virtually sealed off the northern Gaza areas of Jabaliya, Beit Hanoun and Beit Lahiya and leveled large parts of them. Tens of thousands of Palestinians were forced out but thousands are believed to remain in the area, where Kamal Adwan and two other hospitals are located. Troops raided Kamal Adwan in October, and on Tuesday troops stormed and evacuated the Indonesian Hospital. The area has been cut off from food and other aid for months , raising fears of famine . The United Nations says Israeli troops allowed just four humanitarian deliveries to the area from Dec. 1 to Dec. 23. The Israeli rights group Physicians for Human Rights-Israel this week petitioned Israel’s High Court of Justice, seeking a halt to military attacks on Kamal Adwan. It warned that forcibly evacuating the hospital would “abandon thousands of residents in northern Gaza.” Before the latest deaths Thursday, the group documented five other staffers killed by Israeli fire since October. Israel launched its campaign in Gaza vowing to destroy Hamas after the group’s Oct. 7, 2023, attack on southern Israel in which militants killed around 1,200 people and abducted some 250 others. Around 100 Israelis remain captive in Gaza, around a third believed to be dead. Israel’s nearly 15-month-old campaign of bombardment and offensives has devastated the territory’s health sector. A year ago, it carried out raids on hospitals in northern Gaza, including Kamal Adwan, Indonesian and al-Awda Hospital, saying they served as bases for Hamas, though it presented little evidence. Israel’s campaign has killed more than 45,400 Palestinians, more than half women and children, and wounded more than 108,000 others, according to the Health Ministry. Its count does not distinguish between civilians and combatants. More than 90% of Gaza’s 2.3 million Palestinians have been driven from their homes, most now sheltering in sprawling tent camps in south and central Gaza. Children and adults, many barefoot, huddled Friday on the cold sand in tents whose plastic and cloth sheets whipped in the wind. Overnight temperatures can dip into the 40s Fahrenheit (below 10 Celsius), and sea spray from the Mediterranean can dampen tents just steps away. "I swear to God, their mother and I cover ourselves with one blanket and we cover (their five children) with three blankets that we got from neighbors. Sea waters drowned everything that was ours,” said Muhammad al-Sous, displaced from Beit Lahiya in the north. The children collect plastic bottles to make fires, and pile under the blankets when their only set of clothes is washed and dried in the wind. At least three babies in Gaza have died from exposure to cold in recent days , doctors there have said, and the Health Ministry said an adult — a nurse who worked at the European Hospital — also died this week. Khaled and Keath reported from Cairo. Associated Press writer Edith M. Lederer at the United Narions contributed to this report.No. 23 Texas A&M aims to hand Oregon first loss at Players Era

VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Gatos Silver, Inc. (NYSE/TSX: GATO) (“Gatos Silver” or the “Company”) today announced the date of a special meeting of stockholders (the “Special Meeting”) and the filing of its definitive proxy statement in connection with the previously announced Agreement and Plan of Merger (the “Merger Agreement”) with First Majestic Silver Corp. (“First Majestic”) (NYSE/TSX: AG) (FSE: FMV) pursuant to which First Majestic will acquire all of the issued and outstanding shares of common stock of Gatos Silver (the “Transaction”). Gatos Silver notified its stockholders that the Special Meeting will take place virtually on Tuesday, January 14, 2025, at 10:00 a.m., Pacific Time. Stockholders of record as of November 25, 2024 (the “Record Date”) are eligible to vote at the Special Meeting. Gatos Silver stockholders will be asked to vote on the adoption of the Merger Agreement and the adjournment of the Special Meeting in certain circumstances. Gatos Silver’s Board of Directors unanimously recommends that Gatos Silver stockholders vote in favor of both proposals. First Majestic shareholders are required to approve the issuance of the First Majestic common shares in connection with the Transaction, and accordingly, First Majestic has announced that it will hold its shareholder meeting in-person on Tuesday, January 14, 2025, at 11:00 a.m., Pacific Time, one hour following the Special Meeting. For more information regarding First Majestic’s shareholder meeting, see First Majestic’s SEDAR+ profile at www.sedarplus.ca . Subject to the approval of Gatos Silver’s stockholders and First Majestic’s shareholders and the satisfaction or waiver of other conditions precedent, it is anticipated that the Transaction will close in early 2025. Gatos Silver currently expects to send the meeting materials for the Special Meeting to stockholders of record as of the Record Date on or about December 6, 2024; however, delivery of materials to some Canadian stockholders may be impacted by the ongoing Canada Post labour dispute which is affecting the delivery of mail within Canada. Important Information for Investors and Stockholders about the Transaction and Where to Find It This news release is not intended to and does not constitute an offer to buy or sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities of First Majestic or Gatos Silver or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of First Majestic or Gatos Silver in any jurisdiction in contravention of applicable law. This news release may be deemed to be soliciting material relating to the Transaction. In connection with the Transaction between First Majestic and Gatos Silver pursuant to the Merger Agreement and subject to future developments, First Majestic filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form F-4 that includes a Proxy Statement of Gatos Silver that also constitutes a Prospectus of First Majestic (the “Proxy Statement/Prospectus”) and other documents. Each of First Majestic and Gatos Silver may also file other relevant documents with the SEC regarding the Transaction. The registration statement on Form F-4 was declared effective by the SEC on December 2, 2024. Gatos Silver filed a Proxy Statement/Prospectus with the SEC on December 3, 2024 which it plans to mail to its stockholders in connection with the Transaction. First Majestic will also file a management proxy circular in connection with the Transaction with applicable Canadian securities regulatory authorities and First Majestic will deliver its management proxy circular to First Majestic shareholders. This news release is not a substitute for any registration statement, proxy statement, prospectus or other document First Majestic or Gatos Silver has filed or may file with the SEC or Canadian securities regulatory authorities in connection with the pending Transaction. INVESTORS AND SECURITY HOLDERS OF GATOS SILVER AND FIRST MAJESTIC ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND MANAGEMENT PROXY CIRCULAR, RESPECTIVELY, AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC OR CANADIAN SECURITIES REGULATORY AUTHORITIES AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO CAREFULLY IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE TRANSACTION BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT FIRST MAJESTIC, GATOS SILVER, THE TRANSACTION AND RELATED MATTERS. Investors and security holders are able to obtain free copies of the Proxy Statement/Prospectus, the filings with the SEC that are and will be incorporated by reference into the Proxy Statement/Prospectus and other documents filed with the SEC by First Majestic and Gatos Silver containing important information about First Majestic or Gatos Silver and the Transaction through the website maintained by the SEC at www.sec.gov . Investors are also able to obtain free copies of the management proxy circular and other documents filed with Canadian securities regulatory authorities by First Majestic, through the website maintained by the Canadian Securities Administrators at www.sedarplus.ca . In addition, investors and security holders are able to obtain free copies of the documents filed by First Majestic with the SEC and Canadian securities regulatory authorities on First Majestic’s website at www.firstmajestic.com or by contacting First Majestic’s investor relations team. Copies of the documents filed with the SEC by Gatos Silver are available free of charge on Gatos Silver’s website or by contacting Gatos Silver’s investor relations team. Participants in the Merger Solicitation First Majestic, Gatos Silver and certain of their respective directors, executive officers and employees may be considered participants in the solicitation of proxies in connection with the proposed Transaction. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders of First Majestic and the stockholders of Gatos Silver in connection with the Transaction, including a description of their respective direct or indirect interests, by security holdings or otherwise, is included in the Proxy Statement/Prospectus described above and other relevant documents filed with the SEC and Canadian securities regulatory authorities in connection with the Transaction. Additional information regarding First Majestic’s directors and executive officers is also included in First Majestic’s Notice of Annual Meeting of Shareholders and 2024 Proxy Statement, which was filed with the SEC and Canadian securities regulatory authorities on April 15, 2024, and information regarding Gatos Silver’s directors and executive officers is also included in Gatos Silver’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 20, 2024, as amended by Amendment No. 1 to such annual report filed with the SEC on May 6, 2024 and Gatos Silver’s 2024 Proxy Statement for its 2024 Annual Meeting of Stockholders, which was filed with the SEC on April 25, 2024. These documents are available free of charge as described above. About Gatos Silver Gatos Silver is a silver dominant exploration, development and production company that discovered a new silver and zinc-rich mineral district in southern Chihuahua State, Mexico. As a 70% owner of the Los Gatos Joint Venture (“LGJV”), the Company is primarily focused on operating the Cerro Los Gatos mine and on growth and development of the Los Gatos district. The LGJV includes approximately 103,000 hectares of mineral rights, representing a highly prospective and under-explored district with numerous silver-zinc-lead epithermal mineralized zones identified as priority targets. On September 5, 2024, Gatos Silver and First Majestic announced that they entered into the Merger Agreement pursuant to which First Majestic will acquire all of the issued and outstanding common shares of Gatos Silver. The proposed Transaction would consolidate three world-class, producing silver mining districts in Mexico to create a leading intermediate primary silver producer. Information relating to the proposed Transaction can be found at the Company’s website at www.gatossilver.com . Cautionary Note Regarding Forward Looking Statements This news release contains “forward‐looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor created by such sections and other applicable laws and “forward‐looking information” under applicable Canadian securities laws (collectively, “forward‐looking statements”). These statements relate to future events of First Majestic and/or Gatos Silver that are based on assumptions of management of First Majestic and/or Gatos Silver made in good faith in light of management's experience and perception of future developments. Forward‐looking statements in this news release include, but are not limited to, statements with respect to: closing of the Transaction and the terms and timing related thereto; the timing and receipt of required shareholder and other approvals; satisfaction of the conditions to completion of the Transaction; and the anticipated timing of mailing proxy statements and circulars regarding the Transaction. Assumptions may prove to be incorrect and actual results may differ materially from those anticipated. Consequently, guidance cannot be guaranteed. As such, investors are cautioned not to place undue reliance upon guidance and forward‐looking statements as there can be no assurance that the plans, assumptions or expectations upon which they are placed will occur. Actual results may vary from forward‐looking statements. Forward‐looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to materially differ from those expressed or implied by such forward‐looking statements, including but not limited to those factors discussed in (a) the section entitled “Description of the Business ‐ Risk Factors” in First Majestic’s most recently filed Annual Information Form, available under its profile on SEDAR+ at www.sedarplus.ca , and as an exhibit to its most recently filed Form 40‐F available on EDGAR at www.sec.gov/edgar or on First Majestic’s website and (b) the Gatos Silver’s Annual Report on Form 10-K for the year ended December 31, 2023, available on EDGAR at www.sec.gov/edgar or on Gatos Silver’s website. First Majestic is not affirming or adopting any statements or reports attributed to Gatos Silver in this news release or made by Gatos Silver outside of this news release. Gatos Silver is not affirming or adopting any statements or reports attributed to First Majestic in this news release or made by First Majestic outside of this news release. Although First Majestic and Gatos Silver have attempted to identify important factors that could cause actual results to differ materially from those contained in forward‐looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. First Majestic and Gatos Silver believe that the expectations reflected in these forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included herein should not be unduly relied upon. These statements speak only as of the date hereof. First Majestic and Gatos Silver do not intend, and do not assume any obligation, to update these forward-looking statements or forward-looking information, except as required by applicable laws. Investors and Media Contact André van Niekerk Chief Financial Officer investors@gatossilver.com (604) 424 0984The Lagos Chamber of Commerce and Industry (LCCI) has commended the Federal Government 2025 Budget of Restoration, but called for an urgent need to improve Nigeria’s tax-to-GDP ratio to achieve the ambitious revenue target of N34.82 trillion. Reacting to 2025 budget released by Federal Government, the Director General of LCCI, Dr. Chinyere Almona, said Nigeria’s tax-to-GDP ratio is one of the lowest globally. She said “accelerating tax reforms, simplifying processes, and incorporating the informal sector are essential”, stressing that leveraging technology to expand the tax net, minimise leakages, and foster transparency will be critical” She said, “fiscal discipline must complement these efforts to effectively manage the N15.81 trillion debt servicing allocation, adding that prioritising high-impact, self-sustaining projects and exploring alternative funding mechanisms, such as public-private partnerships, are crucial to keeping debts within sustainable limits.” She expressed the need to draw attention to key priorities, including security, infrastructure, education, health, and agriculture, focusing on achieving macroeconomic stability and inclusive growth. Speaking further she said, “structural reforms are indispensable to reducing inflation to 15 per cent and stabilizing the exchange rate at N1,400/$1. “Addressing food and energy supply chain bottlenecks, fast-tracking local petroleum production projects, and fostering alignment between monetary and fiscal policies will restore confidence in the naira and ease inflationary pressures.” She, however, said that achieving the ambitious oil production target of 2.06 million barrels daily requires decisive action to resolve pipeline vandalism, theft, and underinvestment.Digital labels can help grocers waste less food

PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications. Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq. Vincerx is also implementing additional streamlining and cost-control measures, including a workforce reduction, as it pursues due diligence and transaction-related work. As part of this workforce reduction, Dr. Ahmed Hamdy, Chairman and Chief Executive Officer (CEO), has stepped down as CEO but will remain as Chairman. Dr. Raquel Izumi has stepped down as President and Chief Operations Officer and taken over as Acting CEO in a consulting capacity. Alexander Seelenberger has stepped down as Chief Financial Officer, and Kevin Hass, the Company’s Vice President and Controller, has taken over as Acting Chief Financial Officer. Mr. Seelenberger has agreed to provide ongoing assistance in a consulting capacity to assist the Company as it pursues its strategic efforts. “This strategic transaction highlights Vincerx’s commitment to develop ADCs with improved safety profiles that allow patients to thrive on—rather than endure—their cancer therapies,” said Raquel Izumi, Ph.D., Acting Chief Executive Officer. “Oqory’s anti-TROP2 ADC has shown favorable efficacy and safety in the clinic. Among approximately 150 treated patients, results include an 83% overall response rate and 100% disease control rate in first-line triple-negative breast cancer (TNBC; n=30). Unlike other TROP2 ADCs in Phase 3, no cases of interstitial lung disease or Grade 3 and above stomatitis have been reported. Oqory’s Phase 3 studies of OQY-3258 are ongoing to confirm these promising findings.” About OQY-3258 (also known as ESG401) OQY-3258 is Oqory’s anti-TROP2 ADC with an optimized enzyme-dependent linker technology and an SN-38 payload with established efficacy and manageable side effect profile. OQY-3258 has completed Phase 1/2 development in over 150 patients with solid tumors, including metastatic HR+/HER2- and triple-negative breast cancer. OQY-3258 has shown efficacy in these patients, including reduction of brain metastasis and responses in heavily pretreated patients. To date, OQY-3258 has exhibited a differentiated safety profile vs. Trodelvy and other TROP2 ADCs in Phase 3 development. Notably, no interstitial lung disease or ocular surface events have been observed. Gastrointestinal effects have been mild and mainly Grade 1/2. Neutropenia and leukopenia have been the major AEs, which were manageable and did not result in discontinuation of study drug. OQY-3258 is being evaluated in a Phase 3 study as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer ( NCT06732323 ) and in a Phase 3 study in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer ( NCT06383767 ). About Oqory, Inc. Oqory, Inc. is an innovator in the field of ADCs with expertise in advancing targeted cancer therapies. The Company’s pipeline includes multiple ADC programs, with two currently in clinical development and several next-generation ADCs in preclinical stages. These programs are designed to address critical unmet needs in indications such as breast cancer, non-small cell lung cancer, small cell lung cancer, multiple myeloma, and other metastatic solid tumors. Powered by a proprietary ADC platform, Oqory is delivering therapies that have demonstrated promising efficacy and safety paving the way for improved patient outcomes. About Vincerx Pharma, Inc. Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx’s pipeline consists of a next-generation ADC, VIP943, currently in Phase 1; a small molecule drug conjugate, VIP236, which has completed its Phase 1 study; a CDK9 inhibitor, enitociclib, which has completed a Phase 1 monotherapy study; a preclinical ADC, VIP924; and VersAptxTM, a versatile, next-generation bioconjugation platform. Vincerx is based in Palo Alto, California, and has a research subsidiary in Monheim, Germany. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “suggest,” “seek,” “intend,” “plan,” “goal,” “potential,” “on-target,” “on track,” “project,” “estimate,” “anticipate,” or other comparable terms. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, the entry into a definitive merger agreement; the anticipated terms and closing of the merger, the $20 million equity investment, and the amount and timing of the interim financing; the expected ownership structure and value to Vincerx stockholders upon closing of the merger; the anticipated benefits of a merger transaction; and the clinical results of Oqory’s product candidates. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations, and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside Vincerx’s control. Actual results, conditions, and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions, and events to differ materially from those indicated in the forward-looking statements include, but are not limited to, Vincerx’s capital requirements, availability and sufficiency of capital, and cash runway; the ability of the parties to enter into a definitive merger agreement and the final terms thereof; the parties’ ability to satisfy the conditions precedent to the merger, including stockholder approval; the closing of the merger; the risk that any definitive agreement is terminated after it is entered into but before consummation of any proposed merger;; Vincerx’s reliance on receipt of interim funding; market acceptance of the combined company; risks associated with clinical development of the Vincerx and Oqory product candidates; general economic, financial, legal, political, and business conditions; and the risks and uncertainties set forth in Vincerx’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and subsequent reports filed with the Securities and Exchange Commission by Vincerx. Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements. Vincerx and the Vincerx logo are trademarks of Vincerx. This press release also contains trademarks and trade names that are the property of their respective owners. Contacts: Gabriela Jairala Vincerx Pharma, Inc. gabriela.jairala@vincerx.com Totyana Simien Inizio Evoke Comms totyana.simien@inizioevoke.com

ROME (AP) — In 2020, it was a run to the Champions League quarterfinals just as Bergamo was becoming the epicenter of the coronavirus pandemic . Last season, it was an upset victory over Bayer Leverkusen in the Europa League final to end the German club’s European-record unbeaten run at 51 games. Atalanta keeps on surprising and its latest exploit was moving atop Serie A following a 3-1 win at Parma on Saturday for its seventh straight win in the Italian league. And to think that coach Gian Piero Gasperini considered leaving Atalanta toward the end of last season. Now, Gasperini has the chance to guide “La Dea” (The Goddess), as the team is nicknamed, to its first ever Italian league title. There’s a long way to go, though, and it should be noted that Atalanta is level on points with second-place Inter Milan, which routed Hellas Verona 5-0 earlier, and that Napoli has a chance to reclaim the lead when it hosts Roma on Sunday. Also Saturday, AC Milan and Juventus drew 0-0 at the San Siro in a match with few chances from both sides. Milan produced one shot on goal and Juventus created two. Atalanta's Mateo Retegui scored his league-leading 12th goal of the season, Ederson made it 2-0 before the break and Europa League final hero Ademola Lookman restored the two-goal advantage after Matteo Cancellieri had pulled one back for Parma. Retegui’s fourth headed goal of the season put him atop that category across Europe’s five major leagues, according to Opta, while Lookman volleyed in a cross from Juan Cuadrado after having two goals disallowed. Gasperini was sent off midway through the second half for protests. But he was smiling in the stands at the final whistle. Atalanta's 34 goals are the most in Italy, and trail only Barcelona (42), Bayern Munich (36) and Paris Saint-Germain (36) across Europe's top five leagues. Atalanta has won two and drawn two in the Champions League this season. Marcus Thuram scored twice for defending champion Inter at Verona. Inter was missing top striker Lautaro Martinez, who was out sick. But five goals in the first half made Lautaro’s absence a non-issue. Joaquin Correa opened the scoring 17 minutes in, Thuram then scored twice before more goals from Stefan de Vrij and Yann Aurel Bisseck. Correa nearly added another in second-half stoppage time but his effort hit the woodwork. Inter's only loss across all competitions this season was a derby defeat to Milan in September. AP soccer: https://apnews.com/hub/soccer

Upstart Holdings chief legal officer sells $446,284 in stockOn November 25, 2024, the Illinois State Legislature introduced House Bill 5918 IL HB5918 , the Artificial Intelligence Systems Use in Health Insurance Act (“AI Act”). It provides the Illinois Department of Insurance (the “Department”) regulatory oversight of insurers using artificial intelligence for determinations that affect consumers. The proposed bill grants the Department the ability to adopt rules, including emergency rules per the Illinois Administrative Procedure Act, to implement and administer the AI Act. The AI Act requires regulatory oversight of the use of AI systems and disclosure of AI utilization. The focus of the regulatory oversight of AI systems surrounds the use of AI in making or supporting adverse determinations that could affect consumers. The AI Act enables the Department to monitor the conduct of all insurers who operate in Illinois, including insurers’ development, implementation, and use of AI-driven models in coverage determinations. Under the bill, such conduct is subject to investigation or market conduct action. The bill expands the Department’s investigative tools as they may (1) inquire further on relevant questions to specific models, AI systems, or applications of a model or AI system; and (2) also make requests for information and documentation of AI systems governance, risk management, AI use protocols, information and documentation relating to the insurer’s preacquisition and pre-utilization diligence, monitoring, auditing of data or AI systems developed by a third party, and information and documentation relating to implementation and compliance with the insurer’s AI systems program. For insurers operating in Illinois, the AI Act prevents insurers from issuing an adverse consumer outcome on the denial, reduction, or termination of benefits or insurance plans where the insurers solely use an AI system or predictive model. Insurers must meaningfully review such decisions when the use of an AT system or predictive model is involved. To enhance transparency and promote consumer trust, the Department has the ability to adopt rules that may require the insurer to disclose its AI use. While the AI Act itself does not go into further detail on such rules, the Department has the authority to set rules that require full and fair disclosure on the manner and content of the insurers’ AI use. Insurers authorized to conduct business in Illinois must comply with the AI Act. Any decision that impacts the consumer that involves advanced analytical and computational technologies (including AI systems and machine learning), requires the insurers to comply with applicable federal and State laws, regulations, and rules, including both insurance laws and laws addressing unfair trade practices and unfair discrimination. While the AI Act may be a proposed bill, the Centers for Medicare & Medicaid Services (“CMS”) took a stance on AI review of denial, reduction or termination of insurance plans when it issued a Final Rule in April 2023 that became effective in January 2024. CMS’ Final Rule made clear that Medicare Advantage plans must make medical necessity determinations based on the enrollee’s specific circumstances instead of relying on algorithms. Furthermore, such determinations must be reviewed by a physician or appropriate healthcare professional. As more laws and regulations enter the insurance AI space, insurers will need to take a closer look at their compliance programs and policies and adjust their operations. There are numerous risks when using AI and its algorithms, and the growing use of AI in the healthcare and insurance industries has raised significant concerns about the opacity of the AI-driven decisions. Moreover, the increased reliance on AI models for claims adjudication, coverage determinations, and pricing can lead to situations where a consumer is denied coverage or benefits based on factors that are unclear or difficult to understand. As public scrutiny of health insurers is on the rise, the likelihood of AI-focused litigation will also increase. In an ever-evolving and dynamic legal landscape of AI in insurance regulation, it is important for insurers to have their legal teams assist with the review, maintenance, and upkeep of their AI policies. Listen to this post

The Mahayuti alliance secured a sweeping victory in the Maharashtra assembly elections, described as 'historic' by Shiv Sena leader Shaina NC, who highlighted voter support for a 'Viksit Bharat'. However, Shaina NC herself suffered a significant defeat in Mumbadevi, losing to Congress's Amin Patel by 34,844 votes. Narrating this electoral success, Shaina NC expressed pride in the Mahayuti's focus on development. The BJP's leadership, under Eknath Shinde, drove the alliance to success, with the BJP winning or leading in 132 seats, Shiv Sena in 57, and NCP in 41, out of a total of 288 assembly seats. The Maha Vikas Aghadi faced severe setbacks, with Shiv Sena (UBT) winning only 20, Congress 16, and NCP(SP) 10 seats. BJP's impressive strike rate featured wins in 133 of 148 contested seats. Devendra Fadnavis praised the unity under Prime Minister Narendra Modi's vision, ensuring a powerful mandate for Mahayuti. Expressing gratitude, CM Eknath Shinde thanked BJP's central leadership, notably PM Modi, Amit Shah, and J.P. Nadda, for their election campaigning support. His predicted triumph of 200 seats came close to fruition. The victory was heralded by congratulatory calls from Prime Minister Modi and Union Home Minister Amit Shah. (With inputs from agencies.)

outboundIQ Achieves Certified Implementation Partner (CIP) Status with Five9

Delivering Optimized, Outbound-Focused Contact Center Solutions for Modern Businesses LAUDERDALE LAKES, Fla. , Dec. 27, 2024 /PRNewswire/ -- outboundIQ www.outboundiq.com proudly announces its accreditation as a Five9 Certified Implementation Partner (CIP), a distinction that reflects its deep expertise in optimizing and streamlining outbound-focused contact center operations. With a team of seasoned Five9 veterans, expert programmers, and industry thought leaders, outboundIQ is uniquely equipped to help businesses of all sizes unlock the full potential of Five9's Virtual Contact Center platform. Optimized Solutions for Complex Contact Center Needs outboundIQ specializes in providing expedited, outbound-focused contact center implementations, integrating advanced features such as inbound and outbound Voice, SMS, Chat, Email, Salesforce Integration, and other third-party app integrations. Clients can also leverage ongoing optimization engagements and monthly retainers for strategic consulting designed to support long-term, outreach-focused success. "Who better to handle your domain configuration than the experts that understand the outbound contact center world. To be an outbound expert, you must know 3 things; how to configure the domain front end, how the architecture interprets that design, and how carriers respond to your dialing behavior as a result of the build. outboundIQ has the advantage of deeply understanding all 3 things. Our experts are seasoned professionals that will guide toward the best build for your business. You tell us about your business, your needs and your processes, and we will build you a domain fit for purpose. outboundIQ offers best in class Domain Optimization, Implementation and Consulting for customers of all sizes and complexity. Due to our methodology and proprietary automations, we are able to bring our customers' projects to life within accelerated timeframes." - Jessica Clay , VP Support and Services "We launched our business in June and were fortunate to connect with the incredible team at outboundIQ early on. Navigating the world of outbound calling and building efficient prospecting systems isn't easy, but the entire team at outboundIQ brought our vision to life seamlessly. They implemented our ideas quickly and executed them flawlessly. Since partnering with them, our contact rates have significantly improved, our conversions have increased, and our overall business is thriving. We're deeply grateful for this collaboration and look forward to continuing our work together on future endeavors!" - Tim, Lit Financial "I genuinely don't know enough ways to thank the entire outboundIQ team. I inherited a domain riddled with mistakes, tangled beyond belief, and I had essentially planned to scrap the whole thing and start over. That's when this team, led by Jessica Clay's brilliance, took over to understand exactly what I wanted to create and completely revitalized my domain. We are all beyond thankful as they continue to consult for us to this day and I see no reason to stop. Thank you, Jessica, Jason, Rudy, Bruno, Sandy and everyone who gets the pleasure of working with these domain geniuses!" - Michael, Lifetime Home Remodeling A Holistic Approach to Outbound Excellence Creating a competitive, consumer-focused outreach program requires more than just advanced technology. As outboundIQ explains, a thriving contact center functions like a high-performing racing team: outboundIQ's professional services team brings these critical elements together, ensuring clients achieve best-in-class outbound operations that prioritize consumer experience while maintaining a competitive edge. A Call to Collaboration With its new CIP certification, outboundIQ invites businesses to explore select partnership opportunities and projects to reimagine their contact center operations. Whether through expedited implementations or ongoing strategic consulting, outboundIQ is committed to driving measurable results for its clients. About outboundIQ outboundIQ delivers optimized, outbound-focused contact center implementations, combining years of Five9 expertise with cutting-edge strategies to help businesses achieve exceptional outreach outcomes. As a Five9 Certified Implementation Partner, outboundIQ provides tailored solutions to meet the unique needs of modern organizations. About Five9 Five9 is a digital enterprise's leading cloud contact center and software provider. The Five9 Intelligent CX Platform is reliable, secure, compliant, and scalable, designed to create exceptional personalized customer experiences. www.five9.com Media contact: Sandy Tafur Phone: 404-660-5314 mail: sandy@outboundiq.com View original content to download multimedia: https://www.prnewswire.com/news-releases/outboundiq-achieves-certified-implementation-partner-cip-status-with-five9-302339797.html SOURCE outboundIQStock market today: Dow leaps 400 points to fresh high, Russell 2000 notches first record since 2021